Record mula sa primary source
Decision-gradeTopline na resulta
AVTX-009 Phase 2 LOTUS trial sa HS: inaasahan ang topline data sa Q2 2026
Nakumpleto na ng Avalo ang enrollment sa Phase 2 LOTUS trial ng AVTX-009 sa hidradenitis suppurativa. Ang topline results ay naka-guide na ngayon para sa Q2 2026, na nagtatatag ng susunod na regulatory/clinical milestone para sa asset.
Mahahalagang fact
- Na-file
- Dis 2, 2025, 11:38 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
AVTXAvalo Therapeutics- Asset
- AVTX-009
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,
Higit pa tungkol sa asset na ito
Kapansin-pansin
Okt 10, 2025
11:01 AM
AVTXAvalo TherapeuticsAVTX-009 Phase 2 LOTUS trial para sa HS ay nag-eenroll; topline sa kalagitnaan ng 2026